NCT04199819 (OBI) is a NA clinical trial of entecavir in Occult Hepatitis B, sponsored by The University of Hong Kong.

Who is sponsoring NCT04199819?

NCT04199819 is sponsored by The University of Hong Kong.

What drugs are being tested in NCT04199819?

Interventions in NCT04199819: entecavir.

What condition does NCT04199819 study?

NCT04199819 studies Occult Hepatitis B, Liver Transplant; Complications.

Is NCT04199819 still recruiting?

NCT04199819 is currently status unknown. Last updated 23 May 2022.

Last reviewed 2022-05-23 · How we verify

NCT04199819: OBI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Detecting Occult HBV Infection in Liver Donors Positive for Antibody to Hepatitis B Core Antigen (Anti-HBc)

Status unknown NA Last updated 23 May 2022

What this trial tests

NA trial testing entecavir in Occult Hepatitis B in 100 participants. Status unknown.

Timeline

1 January 2022

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	The University of Hong Kong
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 January 2022
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across Hong Kong

Drugs / interventions tested

entecavir (ENTECAVIR) — full drug profile →

Conditions studied

Occult Hepatitis B — all drugs for Occult Hepatitis B →
Liver Transplant; Complications — all drugs for Liver Transplant; Complications →

Sponsor

The University of Hong Kong

Who can join

18 and older, any sex, with Occult Hepatitis B or Liver Transplant; Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

After LT, long-term immunosuppressive therapy is required to prevent organ rejection. Therefore, for organs which may harbour OBI, there is a risk of reactivation which may result in liver graft failure. As a consequence, all patients who receive an anti-HBc positive graft will receive antiviral prophylaxis. Currently, all such patients will be commenced on life-long entecavir, which is highly effective in preventing reactivation.2 One major disadvantage of using such a blanket approach is that a significant proportion of anti-HBc donors may not actually have underlying occult HBV infection, and recipients of such grafts may not require lifelong antiviral therapy. Current markers such as HBsAg and HBV DNA are not sensitive enough to detect the presence of OBI. This is the first trial proposed to look at the efficacy of these novel HBV biomarkers in identifying occult HBV infection when used in combination, and to identify patients who will not need long term antiviral prophylaxis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of entecavir

Trials testing the same drug.

NCT00388674 — Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection · completed

Other The University of Hong Kong trials

Trials by the same sponsor.

NCT05981430 — Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae · NA · not yet recruiting
NCT07478757 — Assessing the Effectiveness of Low-Dose Computed Tomography in Lung Cancer Screening for High-Risk Smokers: A Randomized · NA · not yet recruiting
NCT07448649 — Chatbot-Assisted Advance Care Planning Education for Family Members · NA · not yet recruiting
NCT07484932 — TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer · NA · not yet recruiting
NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04199819 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Hong Kong
Last refreshed: 23 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04199819.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing